Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome by Smith, Amanda M. et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2021 
Functional and epigenetic phenotypes of humans and mice with 
DNMT3A Overgrowth Syndrome 
Amanda M. Smith 
Taylor A. LaValle 
Marwan Shinawi 
Sai M. Ramakrishnan 
Haley J. Abel 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Amanda M. Smith, Taylor A. LaValle, Marwan Shinawi, Sai M. Ramakrishnan, Haley J. Abel, Cheryl A. Hill, 
Nicole M. Kirkland, Michael P. Rettig, Nichole M. Helton, Sharon E. Heath, Francesca Ferraro, David Y. 
Chen, Sangeeta Adak, Clay F. Semenkovich, Diana L. Christian, Jenna R. Martin, Harrison W. Gabel, 
Christopher A. Miller, and Timothy J. Ley 
ARTICLE
Functional and epigenetic phenotypes of humans
and mice with DNMT3A Overgrowth Syndrome
Amanda M. Smith1, Taylor A. LaValle1, Marwan Shinawi 2, Sai M. Ramakrishnan1, Haley J. Abel1,
Cheryl A. Hill 3, Nicole M. Kirkland3, Michael P. Rettig 1, Nichole M. Helton1, Sharon E. Heath1,
Francesca Ferraro1, David Y. Chen 4, Sangeeta Adak5, Clay F. Semenkovich 5, Diana L. Christian6,
Jenna R. Martin6, Harrison W. Gabel6, Christopher A. Miller1 & Timothy J. Ley 1✉
Germline pathogenic variants in DNMT3A were recently described in patients with over-
growth, obesity, behavioral, and learning difficulties (DNMT3A Overgrowth Syndrome/DOS).
Somatic mutations in the DNMT3A gene are also the most common cause of clonal hema-
topoiesis, and can initiate acute myeloid leukemia (AML). Using whole genome bisulfite
sequencing, we studied DNA methylation in peripheral blood cells of 11 DOS patients and
found a focal, canonical hypomethylation phenotype, which is most severe with the dominant
negative DNMT3AR882H mutation. A germline mouse model expressing the homologous
Dnmt3aR878H mutation phenocopies most aspects of the human DOS syndrome, including
the methylation phenotype and an increased incidence of spontaneous hematopoietic
malignancies, suggesting that all aspects of this syndrome are caused by this mutation.
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Overgrowth syndromes are a heterogeneous group of raredisorders that are characterized by a global or localizedtissue hypertrophy; the genetic causes of these syndromes
are emerging as more patients’ genomes are molecularly scruti-
nized. The first report of DNMT3A overgrowth syndrome (DOS,
also called Tatton–Brown–Rahman Syndrome; TBRS; MIM
615879) described a syndrome of increased growth, defined as
height and/or head circumference at least two standard deviations
above the mean, associated with facial dysmorphism and intel-
lectual disability occurring in patients with de novo heterozygous
germline mutations in DNMT3A1. In the initial report, 13/152
patients with overgrowth had mutations in the DNMT3A gene,
and all mutations were located within the functional domains of
the protein. A subsequent publication assessing 55 patients2 and
numerous case reports3–11 confirmed the original findings,
and also described an additional array of mutations scattered
throughout the functional domains of DNMT3A, including mis-
sense, frameshift, and nonsense mutations. For the DOS patients
described to date, the most prevalent mutations alter amino acid
position R882, which is also the most common site of DNMT3A
mutations in patients with AML12. To date, 12/100 patients
identified in the literature have mutations affecting R8822–6,13.
More than 80% of individuals with DOS had overgrowth and a
variable degree of intellectual disability. Obesity (weight of more
than two standard deviations above the age and sex-adjusted
mean) has been reported in two-thirds of patients. A character-
istic facial appearance with heavy, horizontal, and low-set eye-
brows with prominent and enlarged upper central incisors are
frequent findings. Some patients have been reported to have joint
hypermobility, hypotonia, kyphoscoliosis, and afebrile seizures2.
Despite the emerging phenotypic and molecular characteriza-
tion of DOS, limited data are available on the epigenetic con-
sequences of the broad array of DNMT3Amutations seen in these
patients. The precise consequences of most of the DNMT3A
mutations are neither yet clear, nor are genotype: phenotype
correlations for patients with this syndrome.
Somatic mutations in DNMT3A are the most common cause of
clonal hematopoiesis14–16 and are the most common initiating
mutation in AML patients with a normal karyotype17–19.
Although mutations occur throughout the DNMT3A gene in
AML patients, more than half occur at amino acid R882 (e.g.,
R882H, R882C, R882S, R882P, etc.)12. DNMT3AR882 mutations
encode a dominant-negative protein that is thought to act via two
mechanisms: first, R882 mutant proteins fail to homodimerize,
reducing the activity of the enzyme by ~80%, and second, R882
mutant proteins preferentially interact with the wild-type (WT)
protein, creating a catalytic sink that traps the WT protein is
inactive heterodimers (dominant-negative effect)20,21. Previous
studies have shown that the reduced methyltransferase activity of
cells heterozygous for an R882 mutation is associated with a focal,
canonical hypomethylation phenotype at specific regions
within the genomes of AML cells17,20,22. Further, we previously
showed that the morphologically normal peripheral blood cells of
one 9-year-old DOS patient with a heterozygous germline
DNMT3AR882H mutation had a focal hypomethylation phenotype
that was similar to that of AML cells with this mutation22. These
data strongly suggest the hypomethylation phenotype precedes
(and may contribute to) the development of AML. To date, the
global methylation phenotypes of the DOS patients with non-
R882 mutations (defined by WGBS) have not yet been described
and compared to R882 mutations, although array-based methy-
lation studies have been reported5,23. Furthermore, the risk of
developing AML with germline DNMT3A mutations (especially
R882) is not yet clear4.
In this work, we investigate the DNA methylation phenotypes
of peripheral blood cells from 11 DOS patients with DNMT3A
mutations, including three at R882, and eight with alternative
mutations (including one with a heterozygous deletion of the
DNMT3A gene). We also describe the phenotype of mice with a
germline Dnmt3aR878H mutation (the murine homologue of
DNMT3AR882H), which includes many features of the human
syndrome, including obesity, overgrowth, as well as behavioral
and movement deficits. Whole-genome bisulfite and single-cell
RNA-sequencing studies reveal overlapping methylation and
gene-expression phenotypes between mouse and human hema-
topoietic cells. Finally, we show that Dnmt3aR878H mice sponta-
neously develop B-cell and myeloid malignancies with a long
latency, suggesting that patients with DOS should be pro-
spectively monitored for the development of hematologic cancers.
Results
DNMT3A overgrowth syndrome (DOS) patients have focal
hypomethylation in nonleukemic hematopoietic cells. To
determine whether DOS patients have the DNA methylation
changes in the genomes of their hematopoietic cells, we obtained
peripheral blood samples from 11 children and adults with DOS.
Clinical features are summarized in Table 1. Patients ranged in age
from 20 months to 36 years when samples were collected, and all
exhibited hallmarks of DOS, including overgrowth, intellectual
and developmental delays, behavioral disorders (including autism,
anxiety, and panic disorder), hypotonia, and distinct facial fea-
tures. One patient (UPN 894912) was diagnosed with AML
(French Amrican British classification subtype M4) 4 years before
sample banking and was in morphologic complete remission when
the test sample from the peripheral blood was collected. Three
patients (UPN 624400, 154605, and 894912) had R882 mutations,
and the remaining eight had unique mutations occurring
throughout the DNMT3A gene; six were missense mutations, one
was a nonsense mutation (UPN 228211) (Fig. 1a), and one (UPN
518693) had a heterozygous 135 kb deletion that encompassed the
entire DNMT3A gene (Chr2:25,228,254–25,363,376; hg38) (Sup-
plementary Fig. 1a).
To assess the methylation of genomic DNA in the blood cells of
these patients, we performed whole-genome bisulfite sequencing
(WGBS), with a median ~18x coverage of the human genome.
We compared the methylation levels of 11 DOS samples to the
peripheral blood samples of 15 healthy donors aged 4–43 years
(DNMT3A+/+; eight male, seven female). We subcategorized the
DOS patients into two groups: DNMT3AR882 (n= 3; one male,
two female) and DNMT3Anon-R882 (n= 8; five male, three
female) for subsequent analysis, since each non-R882 patient
had a unique mutation. There was no significant difference in age
between control vs. DNMT3AR882 (p= 0.157) or control vs.
DNMT3Anon-R882 (p= 0.824) groups (two-sample t test). Glob-
ally, the methylation levels across the genome were subtly
decreased in DNMT3AR882 and DNMT3Anon-R882 patients
(Fig. 1c). Utilizing established methods24, we identified differen-
tially methylated regions (DMRs) between DNMT3A+/+ (n= 15)
vs. DNMT3AR882 samples (n= 3; Supplementary Data 1), and
DNMT3A+/+ vs. DNMT3Anon-R882 samples (n= 8; Supplemen-
tary Data 2). DMRs were defined as having ≥ 10 CpGs, a mean
methylation difference of ≥ 0.2, a false discovery rate (FDR) of
≤ 0.05, and a standard deviation (SD) of ≤ 0.1 among the test
samples. To ensure that the 2,209 DMRs called in the
R882 samples were independent of age and/or sex effects on
CpG methylation, we used linear regression to test for the effect
of genotype on methylation level while adjusting for sex and log
(age). All of the DMRs remained significant (at FDR < 0.05) in
this regression analysis. At DMRs, the mean methylation values
of DNMT3AR882 samples were lower than the DNMT3Anon-R882
samples at all annotated regions of the genome examined,
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including gene bodies and promoters (p ≤ 0.0001, Fig. 1b, c).
However, the average width of DMRs (in base pairs) in the
DNMT3AR882 samples (662.7 ± 441.6) was not statistically differ-
ent from those in the DNMT3Anon-R882 (614.5 ± 366.8, p=
0.0587; Fig. 1d). Interestingly, the fraction of gene bodies
containing at least one DMR (1426/18951, 7.52%) was signifi-
cantly greater than that observed in other annotated regions of the
genome (0.06–2.4%; ***p ≤ 0.0001; Supplementary Fig. 1b).
The relative severity of the methylation phenotype in the
DNMT3AR882 samples compared to DNMT3Anon-R882 (as well as
the canonicality of the phenotype among samples within a
category) is shown in a heatmap representation of the 2209
DMRs identified by comparing the healthy DNMT3A+/+ donors
vs. DNMT3AR882 samples (Fig. 1e). Passively plotting the
methylation values of the non-R882 samples revealed the
attenuated methylation difference in the same regions in those
samples. In contrast, the direct comparison of DNMT3Anon-R882
samples to healthy donors revealed only 332 DMRs (Fig. 1f). In
both comparisons, all DMRs identified were hypomethylated, and
215 DMRs (65% of DNMT3Anon-R882 and 10% of DNMT3AR882
DMRs) overlapped between DNMT3AR882 and DNMT3Anon-R882
samples (where overlap required at least 1 bp of shared sequence).
An example of a region within the HOXB cluster with DMRs
(highlighted by black boxes) is shown in Fig. 1g, along with two
striking DMRs in exons four and five of the RASIP1 gene, that are
specific for the R882 samples (Fig. 1g). The DMRs present in
these regions are more pronounced in the R882 mutant samples,
suggesting that R882 mutations cause a greater reduction in DNA
methyltransferase activity than the non-R882 mutations.
DNMT3AR882 alters the transcriptional signatures of hemato-
poietic cells. Utilizing the 10x Genomics Chromium platform25,
we performed single-cell RNA-sequencing (scRNA-seq) on fresh
peripheral blood samples from UPN 624400 (at age 14) and his
unaffected male sibling (at age 17). The two samples showed a
high level of similarity (Supplementary Fig. 2a). Graph-based
clustering identified 12 clusters that were functionally categorized
with ToppGene26 by inputting the top 50 identifying genes for
each cluster (Fig. 2a). These populations were then validated by
the assessment of well-established gene markers enriched in dif-
ferent subsets (Supplementary Fig. 2b). The cell type distribution
was different between the DNMT3AR882H patient and his sibling
control (p < 0.0001, chi-squared), and subtle differences in several
individual populations (relative to total cells) were observed
(Fig. 2b). The fraction of CD4+ naïve T-cells (cluster 5) was
reduced (13.94–4.77%), and the NK-cell (cluster 8) and NKT
(cluster 10) fractions were increased (3.09–15.88% and
3.80–7.01%, respectively, Fig. 2b). The reduction in T-cells and
increase in NK-cells was orthogonally validated by 15-color flow
cytometry of the same samples (Supplementary Fig. 2c). We
identified differentially expressed genes in each cluster in the
DNMT3AR882H vs. sibling control samples with a p-value and
expression cutoff of 0.05 and log2 ratio of ±1, respectively
(Supplementary Data 3). Out of 12 clusters, nine had differen-
tially expressed genes (DEGs; Fig. 2c); however, the total numbers
of DEGs were relatively small, ranging from five (cluster 11) to 72
(cluster 1). Interestingly, 50 genes were identified as dysregulated
in two or more clusters, and their dysregulation was canonical
across cell types, suggesting they were dysregulated by mechan-
isms not specific to lineage or cell type (Fig. 2d). For example, the
RASIP1 gene (which contains two DMRs; Fig. 1g) was upregu-
lated in 7/9 clusters with detectable DEGs (Fig. 2e). This was due
to an increase in the number of expressing cells, rather than an
increase in the expression level of RASIP1 per cell, since the
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expression, while in the DNMT3AR882H sample, 15% of cells had
detectable reads. In contrast, HOXB genes, also associated with
DMRs, were downregulated across multiple cell types. HOXB2
was downregulated due to a decrease in the number of expressing
cells, and significantly decreased mean reads per cell (Fig. 2e).
However, there was no direct correlation between DMR location
and expression of the HOXB genes, suggesting there may be
additional local or long-range regulatory elements within the
cluster that influence the expression of HOXB genes27. Gene
Ontology terms for DEGs by cluster identified numerous
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biological processes, including the terms related to T-cell activa-
tion and proliferation (IL-4 and IFNG signaling), and vascular
function (angiogenesis and endothelial cell migration) (Supple-
mentary Fig. 2d).
Across all 12 clusters, there were 242 differentially expressed
genes in total; only 38 of these were within 10 kb of a DMR
(Supplementary Fig. 2e). This suggests that for the majority of
DEGs, there is no direct correlation to a local DMR. Using bulk
RNA-sequencing, we confirmed the presence of DEGs in this
DNMT3AR882H patient, as well as one additional DNMT3AR882H
patient (aged 1.7 years), including validation of RASIP1 and
HOXB2 dysregulation (Supplementary Fig. 2f, g). While bulk
RNA-seq was able to identify additional DEGs (in part to
increased sequencing depth), the lack of a global correlation
between differential gene expression and DMRs was recapitu-
lated, even across specific annotated regions of the genome
(Supplementary Fig. 2h and Supplementary Data 4).
Mice with germline Dnmt3aR878H/+ exhibit overgrowth and
obesity. To achieve germline expression of the Dnmt3aR878H/+
allele from its endogenous locus, we utilized the model estab-
lished by Guryanova et al. a minigene combining exons 23 and 24
carrying the point mutation encoding R878H was inserted in the
place of the endogenous Dnmt3a+/+ exon 23 downstream of a
lox-stop-lox cassette28. Heterozygous Dnmt3aR878H/+ mice were
crossed with B6.C-Tg(CMV-cre)1Cgn/J deleter mice. The floxed
founder line mice with Dnmt3aR878H/+ and CMV-cre were then
backcrossed to C57Bl/6 J mice to transmit the mutant allele
through the germline, and to select for mice without CMV-Cre.
Heterozygous floxed Dnmt3aR878H/+ mice were born at the
expected ratios (for over 30 genotyped litters, the ratio of
Dnmt3aR878H/+ to Dnmt3a+/+ was 1.105) and were viable, sur-
viving to 2+ years. Expression of the R878H allele after floxing
was virtually identical to that of the WT allele28. Dnmt3aR878H/
R878H mice were severely runted at birth, and did not survive past
1 week of age. Female heterozygous Dnmt3aR878H/+ mice had a
significant incidence of dystocia during pregnancy, and were
therefore not utilized to produce experimental mice. All experi-
mental mice were generated by crossing male heterozygous
Dnmt3aR878H/+ germline mice (CMV-Cre negative) with C57Bl/
6 J female mice. Germline Dnmt3aR878H/+ mice had normal
weight and size at birth, and no obvious developmental defects.
Many DOS patients have increased height and obesity2. We
therefore tracked weight for heterozygous mutant Dnmt3aR878H/
+ mice (n= 120; 59 females, 61 male) and Dnmt3a+/+ littermate
controls (n= 90; 48 females, 42 male) from 21 to 600 days of age.
Before 100 days of age, there was no difference in weights of the
two cohorts (p= 0.5781 for genotype*time). However, with
aging, the weights of the R878H mice diverged from littermate
controls, reaching a mean of 37.73 and 31.2 g at 380 days of age,
respectively (p ≤ 0.0001 for genotype*time; Fig. 3a). Visual
inspection revealed a clear size difference for the mutant mice
at 1 year of age (Fig. 3b). CT scans performed on four pairs of
210-day old mice showed significantly longer femur lengths (but
not humerus lengths), which represents a surrogate for increased
height (Fig. 3c–e). We also measured craniofacial landmarks to
determine whether Dnmt3aR878H/+ mice had macrocephaly, a
phenotype often observed in DOS children1,2. Although statistical
analyzes of skull measurements did not show a difference in head
circumference (length of and width of the neurocranial bones), some
features of the skulls of Dnmt3aR878H/+ mice are slightly larger than
their WT littermates, including the mandible and localized structures
in the cranium (Fig. 3f). The MRI measurements of body
composition revealed a significant, age-dependent increase in body
fat (Fig. 3g), but not lean mass (Fig. 3h) paralleling the obesity
phenotype observed in DOS patients. Obesity was not associated with
an increase in food consumption; Dnmt3aR878H/+ mice ate
significantly less chow than WT-aged matched controls (mean=
3.51 ± 0.07 vs. 4.33 ± 0.17 grams/mouse/day, p= 0.0013; Fig. 3i). In
addition, metabolic cage analysis confirmed that Dnmt3aR878H/+
mice ate less, a finding that was associated with slightly (albeit not
significantly) reduced movement and overall speed of movement
(Supplementary Fig. 3a–c). The metabolic cage analysis also revealed
that Dnmt3aR878H/+ mice under 6 months of age did not have
significant differences in O2 consumption or CO2 expiration
(although both trended toward reduced levels; Supplementary
Fig. 3d, e). In mice over 6 months of age, there was a decrease
(although not significant) in O2 consumption and a significant
decrease in CO2 production (p= 0.0313). Together, this suggests that
there is a slight decrease in the respiratory quotient (RQ) in
Dnmt3aR878H/+ mice (Supplementary Fig. 3f); although not
significant, this change may indicate a subtle reduction in basal
metabolic rate in these mice, contributing, at least in part, to obesity.
The obesity phenotype was exacerbated by feeding a high-fat diet,
which did not cause a similar weight gain in Dnmt3a+/+ littermates
(Fig. 3j). Finally, we fasted mice for 6 h, and then assayed plasma for
common analytes relevant to increased adiposity. The plasma levels
of leptin, triglycerides, cholesterol, glucose, and free fatty acids were
not significantly different between Dnmt3aR878H/+ and Dnmt3a+/+
control mice (Supplementary Fig. 3g–o).
Mice with germline Dnmt3aR878H/+ exhibit behavioral
abnormalities. To assess behavioral and neurological phenotypes in
the Dnmt3aR878H/+ mice, we carried out a battery of tests on lit-
termate and age-matched cohorts of WT and R878H mice (all mice
were 100–200 days old at the time of testing, Fig. 4 and Supple-
mentary Fig. 4); and the measurement goals are detailed in the
“Methods” section. A number of results were significantly altered in
Dnmt3aR878H/+ mice, including reduced total ambulations and
rearing events in 1 h open field tests, reduced pole climb down and
inverted screen (60 and 90°) climb-up times, increased time spent
freezing in contextual, conditional and cued fear testing, differential
Fig. 1 Peripheral blood cells of DOS patients with DNMT3AR882 mutations have a more severe methylation phenotype than non-R882 mutations. a
Distribution of germline DNMT3A mutations identified in DOS patients from this study. b Density plot of methylation values from whole-genome bisulfite
sequencing (WGBS) for CpGs within DMRs for each peripheral blood sample from healthy donors (red; n= 15), DNMT3AR882 (blue, n= 3), and
DNMT3Anon-R882 (green, n= 8) patients. c Mean methylation values for both global CpGs and DMR-associated CpGs in specific, annotated regions of the
genome. Hypothesis testing was performed via two-way repeated-measures ANOVA with Tukey’s multiple comparison test within each genomic region.
(ns = not significant, **p≦ 0.01, ****p≦ 0.001). d Mean Size (in bp) of DMRs identified in DNMT3AR882 (n= 2,209) and DNMT3Anon-R882 (n= 332)
peripheral blood samples (P= 0.0587, two-tailed t test). e Heatmap showing the mean methylation values for the 2209 DMRs defined in b for each
individual healthy donor and DNMT3AR882 sample. The values for the same DMRs were also plotted passively for DNMT3Anon-R882 samples (age and sex
shown below). f Heatmap showing the mean CpG methylation values for the 332 DMRs defined by comparing the healthy donors and DNMT3Anon-R882
samples. Values for the same DMRs were plotted passively for DNMT3AR882 samples (age and sex shown below). g Examples of DMRs within the HOXB
cluster and RASIP1 gene. Healthy donors are shown in red, DNMT3AR882 cases in blue, and DNMT3Anon-R882 cases in green. Gene tracks are shown below,
and DMRs are designated in boxes. DMR differentially methylated region, bp base pairs, TSS transcriptional start site.
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foot-shock response, and reduced marble-burying (Fig. 4a–k,
respectively). Outcomes that were not statistically different in R878H
mice included the sensorimotor battery, such as balance (ledge test
and platform test), walking initiation, grip strength (inverted screen
test) and motor coordination (rotarod), as well as the intellectual
disability, memory and anxiety tests, including the elevated plus
maze, Morris water maze test, probe trial (Supplementary Fig. 4).
These data indicate that Dnmt3aR878H/+ mice display reductions in
volitional movement with an absence of frank changes to exploratory
behavior, suggestive of complex emotionality in these mice. Overall,
the behavioral analyses demonstrated that germline Dnmt3aR878H/+
mice have a predominant phenotype of volitional movement deficits,
accompanied by complex emotionality, and subtle cognitive
alterations.
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Fig. 2 Peripheral blood cells of a DOS patient with an DNMT3AR882 mutation have differentially expressed genes. a tSNE projection of scRNA-seq data
from peripheral blood derived from one DOS patient with an R882 mutation (right; UPN 624400, age 14 at collection) and his matched DNMT3A+/+
sibling control sample (left; UPN 978897, age 17 at collection). Graph-based clustering identified 12 distinct clusters that were functionally categorized by
gene-expression analysis utilizing Toppfun. b The percentage contribution of each graph-based cluster associated with scRNA-seq data shown in Panel a.
c Numbers of upregulated (red bars) and downregulated (blue bars) genes in each graph-based cluster. d The heatmap of 50 differentially expressed genes
identified as dysregulated in more than one graph-based cluster. e Examples of two differentially expressed genes (HOXB2 and RASIP1) identified in more
than one graph-based cluster (highlighted in Panel d with red arrows) and associated with a differentially methylated region; tSNE projections, mean read
counts per cell + SEM, and percentage of cells expressing each gene are shown (P-values by t test or Fisher’s exact test for ratio’s are indicated, n= 1
biologically independent samples per genotype). DEG differentially expressed genes.
Fig. 3 Germline Dnmt3aR878H/+ mice exhibit overgrowth and obesity. a Weight in grams of Dnmt3a+/+ control mice (red, n= 90) and Dnmt3aR878H/+
mice (blue, n= 120) from weaning (day 21) to 575 days of age. Linear regression analysis was used to determine differences between genotypes (p≤
0.0001). b Representative image of age and gender-matched littermate Dnmt3a+/+ (30.9 g) vs. Dnmt3aR878H/+ (59.45 g) mice highlighting a typical size
difference at 1 year of age. c Representative CT images of femurs from whole mouse imaging. Measurements of femur length (mm) in Dnmt3a+/+ and
Dnmt3aR878H/+ age-matched controls are shown (n= 4 each genotype). d Quantification of femur lengths (mm) measured as shown in b (n= 4
biologically independent samples/genotype, P= 0.0049 by two-tailed t test). e Quantification of humerus lengths (mm) in the same mice, measured by
CT scan (n= 4 biologically independent samples/genotype, p-value by two-tailed t test). f Reconstructions of cranium and mandible from CT scans of
Dnmt3a+/+ and Dnmt3aR878H/+ mice showing landmarks of differences in size and angles. g The MRI quantification of body fat composition of age-
matched Dnmt3a+/+ (red, n= 4) and Dnmt3aR878H/+ (blue, n= 7) pairs separated by age (less or greater than 6 months), to highlight age-dependent
increases in body fat (P-values by two-way ANOVA with Tukey’s multiple comparisons test are indicated). h The MRI quantification of lean body
mass composition of age-matched Dnmt3a+/+ (red, n= 4) and Dnmt3aR878H/+ (blue, n= 7) pairs separated by age (less or greater than 6 months).
i Quantification of chow consumed (calculated as grams of chow per mouse per day) for age-matched Dnmt3a+/+ (red, n= 8) and Dnmt3aR878H/+ (blue,
n= 8) mice (P= 0.0013 by two-tailed t test). j Weight tracking in grams of Dnmt3a+/+ control mice (red, n= 4) and Dnmt3aR878H/+ mice (blue, n= 6)
fed a high-fat diet from 100 to 300 days of age. Linear regression analysis was used to determine differences between genotypes (p≤ 0.0001). For d, e, g-i
error bars show mean ± SEM. g grams, mm millimeter.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24800-7 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:4549 | https://doi.org/10.1038/s41467-021-24800-7 |www.nature.com/naturecommunications 7
Germline Dnmt3aR878H/+ mice have a focal hypomethylation
phenotype in nonleukemic hematopoietic cells. To understand
the methylation phenotypes of bone marrow cells derived from
unmanipulated, littermate-matched Dnmt3a+/+ (n= 10;
2–52 weeks of age, five male, five female) or Dnmt3aR878H/+ mice
(n= 6; 8–38 weeks of age, three male, three female), we per-
formed WGBS. There was no significant difference in age
between control and Dnmt3aR878H/+ groups (p= 0.779; two-
sample t test). We also included the bone marrow cells from
unmanipulated germline Dnmt3a-/- mice (n= 4; 2 weeks of age,
two male, two female) and Dnmt3a+/- mice (n= 4; 12–52 weeks
of age, three male, one female) as comparators to calibrate the
methylation phenotypes of Dnmt3aR878H/+ relative to deficiency
or haploinsufficiency. The DNA methylation phenotypes of
Dnmt3a-/- 29 and Dnmt3a+/- 30 models have been described in
the literature31–33, and will not be further discussed here.
Fig. 4 Germline Dnmt3aR878H/+ mice exhibit behavioral alterations. a Total ambulations during 1-hour open-field testing, split into 10-minute intervals
(p= 0.0013 effect by genotype, F(1,32)= 12.5, n= 17,17; two-way repeated-measures ANOVA with Šídák’s multiple comparison test). b The number of
rearing events during 1-hour open-field testing, split into 10-minute intervals (p= 0.0183 effect by genotype, F(1,32)= 6.183, n= 17,17; two-way repeated-
measures ANOVA with Šídák’s multiple comparison test). Dnmt3aR878H/+ mice take significantly longer to c climb down a pole (p≤ 0.0001, n= 17,17;
unpaired t test), reach the top of a d 60° inclined screen (p= 0.0041, n= 17,17; unpaired t test) and e 90° inclined screen (p= 0.0118, n= 17,17; unpaired
t test). Panels f–h The percentage of time freezing in f conditioned fear training (cue: p≤ 0.0001 genotype effect, F(1,31)= 28.02, n= 16,17; two-way
repeated-measures ANOVA with Šídák’s multiple comparison test), g contextual fear trials (p= 0.0002 genotype effect, F(1,31)= 18.53, n= 16,17; two-way
repeated-measures ANOVA with Šídák’s multiple comparison test) and h cued fear trials (baseline: p= 0.0009 genotype effect, F(1,31)= 31.02; cue: p=
0.0026 genotype effect F(1,31)= 10.76, n= 16,17; two-way repeated-measures ANOVA with Šídák’s multiple comparison test). i Minimum shock needed to
exhibit a behavioral response in mice during conditioned fear test (escape: p= 0.0064 genotype effect F(1,31)= 5.094, n= 16,17; two-way repeated-
measures ANOVA with Šídák’s multiple comparison test). The box extends from 25th to 75th percentile, the line indicates median and whiskers show 10th
to 90th percentile. j Marbles buried in 30min (5 min bins, p= 0.0181, genotype effect F(1,28)= 6.307, n= 15,15; two-way repeated-measures ANOVA with
Šídák’s multiple comparison test). *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001. The line and bar graphs indicate the mean and SEM for each value
tested. min minutes, s seconds, mA milliamps.
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Our WGBS sequence coverage (median of 18x) assessed 98% of
individual CpGs in the mouse genome. The methylation values
had Pearson’s correlation r > 0.8 within samples for each
genotype, highlighting the reproducibility between biological
replicates, despite the range in ages for the mice used in the study.
Globally, the mean methylation differences among all CpG sites
in the Dnmt3aR878H/+ bone marrow samples were not signifi-
cantly different from the Dnmt3a+/+ samples (Fig. 5a). In
contrast, Dnmt3a-/- samples had significantly reduced mean
global methylation across all CpGs. We next defined DMRs
(using the same parameters used for the human samples)
for Dnmt3a+/+ vs. Dnmt3aR878H/+ samples (#DMRs= 2172,
Supplementary Data 5), Dnmt3a+/+ vs. Dnmt3a-/- samples
(#DMRs= 20161, Supplementary Data 6), and Dnmt3a+/+ vs.
Dnmt3a+/- samples (#DMRs= 8, Supplementary Data 7) and
found that the Dnmt3aR878H/+ phenotype was intermediate
between the Dnmt3a-/- and Dnmt3a+/+ mice (Fig. 5b). To ensure
that the 2172 DMRs called in the R878H samples were
independent of age and sex effects on CpG methylation, we used
linear regression to test for the effect of genotype on methylation
level, while adjusting for sex and log(age). All of the DMRs
remained significant (at FDR < 0.05) in this regression analysis.
Comparison of the 2172 Dnmt3aR878H/+ -specific DMRs with the
Dnmt3a-/- samples revealed virtually complete overlap, but the
degree of methylation reduction in the Dnmt3aR878H/+ samples
was uniformly less severe. Within those 2172 DMRs,
Dnmt3aR878H/+ samples had a mean CpG methylation value of
50.10%, Dnmt3a-/- DMRs had a mean methylation value
of 33.35%, and Dnmt3a+/- DMRs had a mean methylation value
of 85.5% compared to that of Dnmt3a+/+ controls (defined as
having 100% methylation within the same DMRs). This trend was
observed across all annotated regions of the genome and suggests
that the Dnmt3aR878H protein behaves as a dominant-negative at
all functional regions of the genome (Fig. 5a). In addition, the
mean size of DMRs was 890.1+ /− 552 bp for Dnmt3a-/-
samples, 751.1+ /− 474.2 bp for the Dnmt3aR878H/+ samples,
and 610.3+ /− 295.7 bp for the Dnmt3a+/- samples (Fig. 5c).
Of 22,026 gene bodies annotated in the mouse genome, 1375
(6.24%) contained at least one DMR (Supplementary Fig. 1c), a
significant enrichment compared to other annotated regions in
the genome (p ≤ 0.0001). In human peripheral blood, 7.52% of
gene bodies contained a DMR (Supplementary Fig. 1b). The
fractions of other annotated regions associated with DMRs were
also similar between human and mouse samples, suggesting there
is an overlap of the functional consequences of human R882 and
mouse R878H mutations.
The focal and canonical nature of the 2172 and 20,161 DMRs
identified in Dnmt3aR878H/+ and Dnmt3a-/- bone marrow
samples, respectively, are highlighted in Fig. 5d, e. The
methylation pattern across all samples within a genotype was
highly reproducible. From these heatmaps, it was also clear that
essentially all DMRs in Dnmt3aR878H/+ samples are likewise
hypomethylated in the Dnmt3a-/- samples. An intersection
analysis revealed that 81.4% of Dnmt3aR878H/+ DMRs were also
detected in Dnmt3a-/- samples; in contrast, the Dnmt3a+/-
samples had very few DMRs and most closely resembled
Dnmt3a+/+ samples (Fig. 5d). The dramatic methylation loss at
DMRs in Dnmt3a-/- bone marrow was less severe in the
Dnmt3aR878H/+ samples (Fig. 5e). Examples of the focality and
canonicality of methylation changes at specific, homologous loci
are demonstrated for the Hoxb cluster and the Rasip1 gene
(Fig. 5f), where similarly located DMRs were detected in human
R882 samples. To compare DMRs across species we used the
UCSC lift-over tool (http://genome.ucsc.edu) to translate the
human R882 DMR coordinates to the mouse genome, and found
that 101 human DMRs (4.6%) directly corresponded to a mouse
R878H DMR and 1713 (77.5%) were within 10 kb of a mouse
DMR. Conversely, when we lifted the mouse coordinates over to
the human genome, 95 (4.37%) mouse DMRs intersected directly
with a human DMR, and 1889 (87%) were within 10 kb of a
human R882 DMR.
Germline Dnmt3aR878H/+ mice have differentially expressed
genes in specific hematopoietic cell types. We performed
scRNA-seq on whole bone marrow cells from two pairs of
Dnmt3a+/+ and Dnmt3aR878H/+ mice using the 10x Genomics
Chromium platform30. One littermate-matched pair was eval-
uated at 1 month of age, and the other at 9 months, and the
paired samples showed remarkable similarity by tSNE (Supple-
mentary Fig. 5a). After processing aligned data with Partek Flow
software, we performed graph-based clustering and ToppGene
analysis to identify functional cell types based on the top 50
defining genes for each cluster (Fig. 6a, b). Inferred lineages for
each cluster were verified using a k-nearest neighbor algorithm
trained on the Haemopedia Database34 (Supplementary Fig. 5b),
and all lineages were present in both genotypes (Fig. 6a, b, Sup-
plementary Fig. 5a–c). There were subtle, yet significant, differ-
ences in pre-B-cells, monocytes, macrophages, and MPPs in the
Dnmt3aR878H/+ bone marrow relative to controls (by Fisher’s
exact tests for ratios) suggesting that the expression of germline
R878H does not lead to large disturbances in normal hemato-
poietic populations. Graph-based clustering identified one
population that was expanded in the 9-month Dnmt3aR878H/+
sample that did not fit into a single lineage assignment because it
had both B-cell and myeloid gene-expression signatures (cluster
14; mixed lineage).
We next assessed how many differentially expressed genes
overlapped between the 1- and 9-month samples (6047 and 5573
unique DEGs, respectively across 24 clusters), and found 2,775
DEGs common to both ages (Supplementary Data 8). A
comparison of differentially expressed genes identified in
scRNA-seq data from DNMT3AR882 human peripheral blood
(242 total unique DEG across 12 clusters, Fig. 2) and mouse
Dnmt3aR878H/+ bone marrow (8,845 total genes across 1- and 9-
month timepoints) showed concordant dysregulation for 121
genes (50% of human genes) based on gene name alone. We show
examples of conserved dysregulation in the Hoxb gene cluster
(Hoxb4; Fig. 6c) and for Rasip1 (Fig. 6d).
To further validate the dysregulation of Hoxb gene expression
in Dnmt3aR878H cells, we evaluated its expression in a previously
published Dnmt3a-/- scRNA-seq dataset that also utilized a
doxycycline-inducible, WT DNMT3A transgene to restore DNA
methylation29. Inducing DNMT3A activity by feeding mice dox
chow results in time-dependent remethylation at DMRs, with
partial remethylation of the Hoxb locus occurring at approxi-
mately 24 weeks (Supplementary Fig. 6a)29. In Dnmt3a-/-
hematopoietic cells from these mice, Hoxb4 expression was
likewise decreased, predominantly in myeloid lineage cells
(PMNs; Supplementary Fig. 6b, monocytes; Supplementary
Fig. 6c, and GMPs; Supplementary Fig. 6d); restoring DNMT3A
expression with doxycycline in vivo led to a time-dependent
increase in mean Hoxb4 expression per cell, and an increase in
the fraction of myeloid cells expressing Hoxb4 (Supplementary
Fig. 6b–d). These data suggest that the DNA methylation status of
the Hoxb cluster may directly influence the expression of
Hoxb genes.
Hematopoietic phenotypes and spontaneous leukemias in
germline Dnmt3aR878H/+ mice. The sizes of cell populations
defined in the scRNA-seq data suggest that steady-state hemato-
poiesis is relatively unperturbed in Dnmt3aR878H/+ mice. Using 21
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color flow cytometry, we verified this data in a larger cohort of
mice, assessing both peripheral blood and bone marrow cells from
Dnmt3a+/+ and Dnmt3aR878H/+ mice ranging from 1 month to 2
years of age (Supplementary Fig. 7). There were very few pertur-
bations in mature cell populations (B-, T-, erythroid and myeloid
cells), stem populations, or progenitor populations, although age-
related alterations were observed for both genotypes.
We next asked whether Dnmt3aR878H/+ derived hematopoietic
cells would exhibit defects following the stress of a cytotoxic
challenge with doxorubicin and cytarabine; however, there were no
significant differences in count recovery for the Dnmt3aR878H/+mice
(Fig. 7a). Regardless, spontaneous, fatal hematopoietic malignancies
arose in six out of 80 unmanipulated Dnmt3aR878H/+ mice after 1
year of age, vs. 0/65 WT mice (p= 0.0296; Fig. 7b). Flow cytometry
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and morphologic examination using the Bethesda criteria35,36 by a
board-certified hematopathologist were used to classify two samples
as MDS with maturation (mLeuk1 and mLeuk2), two as B-cell
malignancies with extensive plasma cells in the bone marrow and
spleen (mLeuk3 and mLeuk4), one as AML without differentiation
(mLeuk5), and one as CMML-like (mLeuk6) (Fig. 7c and d).
Discussion
In this report, we describe DNA methylation alterations and their
consequences in human patients, and a mouse model of the
DNMT3A Overgrowth Syndrome (DOS). The peripheral blood of
DOS patients had focal, canonical DNA hypomethylation that
was more severe in patients with mutations that altered amino
acid R882, but present in all patients with non-R882 mutations.
In mice with a germline Dnmt3aR878H/+ mutation, we found
similarities to human patients for methylation and gene-
expression patterns, as well as similar growth and behavioral
alterations, strongly suggesting that this mutation can cause the
syndrome. This model supports the observation that patients with
clonal hematopoiesis caused by mutations in DNMT3A can live
for many years without clinical progression to AML14–16,37.
Similar to patients with clonal hematopoiesis, some mice with
Dnmt3aR878H/+ develop spontaneous hematologic malignancies
after long latent periods.
All of the germline DNMT3Amutations examined in this study
caused a focal methylation phenotype in the hematopoietic cells
of DOS patients, suggesting that DOS-associated DNMT3A
mutations must cause a loss of DNA methyltransferase activity.
However, the hypomethylation phenotype of patients with R882
mutations was much more severe than that of non-R882 muta-
tions, consistent with the observation that R882 mutations cause
a dominant-negative effect in hematopoietic cells20,22. The
patients with DNMT3AR882 mutations had a total of 2,209 DMRs
identified in their peripheral blood cells, while patients with non-
R882 mutations had one-tenth that number. By coincidence, one
patient had a true haploinsufficient state (UPN 518693), due to a
heterozygous ~135 kb deletion that encompassed the entire
DNMT3A gene (Table 1, Supplementary Fig. 1). This patient’s
methylation phenotype defined the consequences of simple
haploinsufficiency due to gene deletion. Since all of the other
non-R882 missense mutations had a similar magnitude of
methylation loss (Fig. 1), we suggest that the non-R882 mutations
in this study may all lead to functional deficits that mimic the
inactivation of the affected allele. However, the mechanisms of
inactivation are almost certainly multifarious. The canonically
hypomethylated DMRs in the non-R882 patients affected many
of the same regions as in the R882 samples; 215/332 DMRs (65%)
were concordant, suggesting that these regions may be highly
relevant for epigenetic changes that alter the state of hemato-
poietic stem cells, rendering them more susceptible to
transformation.
As noted in similar studies22,29, the global correlation between
DMRs and altered gene expression is relatively weak in the
hematopoietic cells of the DOS patients. However, two example
genes highlighted in this study (HOXB2 and RASIP1) had
reproducible but opposite alterations in gene-expression patterns
that were associated with local DMRs. Hoxb4 expression and
methylation correlations have previously been reported in a
Dnmt3a deficient serial transplantation model32. Globally, how-
ever, no strong correlative rules could be established for the
expression of genes in close proximity to DMRs in peripheral
blood cells, even when restricted to specific functional regions in
the genome (Supplementary Fig. 2). Similar findings were
reported in a parallel yet unique model of complete Dnmt3a
loss29. Clearly, the expression of genes near DMRs are strongly
influenced by other factors, including genomic context (exon vs.
intron, early vs. late exon, etc.), transcription factor and protein
networks, chromatin modifications, and long-range DNA inter-
actions, none of which have yet been adequately explored in an
integrated analysis.
The germline Dnmt3aR878H/+ mouse model phenocopies
many key aspects of the human syndrome. Age-related weight
gain was associated with increased body fat content (with no
change in lean mass), suggesting that these mice were indeed
obese; obesity was exacerbated with high-fat diet but was not
associated with overeating, and its physiologic basis was not
revealed by standard metabolic studies. Epigenetic variability is
associated with human obesity and can be altered by inheritance,
diet, aging, and the intrauterine environment38. Behavioral tests
revealed that Dnmt3aR878H/+ mice had reduced exploratory
behavior, volitional movement deficits, and complex changes in
learning and memory or anxiety-like behaviors often observed in
DOS patients. While movement, coordination, memory, learning,
and anxiety are intertwined, untangling these relationships in
future studies will be important for understanding specific con-
tributions of individual mutations to phenotypes in DOS patients.
This model shows more locomotive deficits and less autism-like
behaviors than noted in haploinsufficient mice39, suggesting
possible specific genotype: phenotype relationships for different
Dnmt3a mutations. Furthermore, movement deficits, which may
be a consequence of behaviors, may contribute to the weight
phenotype (or vice versa), and therefore, may have important
implications for the development of obesity in DOS patients.
Further studies of brain methylation phenotypes will be required
to fully elucidate epigenome: phenotype correlations in these two
models of DOS.
There are a number of epigenetic similarities between DOS
patients and mice with germline Dnmt3aR878H/+ mutations. We
identified 2172 DMRs in the bone marrow cells of Dnmt3aR878H/+
mice, while 2209 were identified in the blood cells of
DNMT3AR882 DOS patients. Because the age and sex of the
samples from both species were well matched, it is very unlikely
Fig. 5 Germline Dnmt3aR878H/+ mice exhibit focal, canonical DNA hypomethylation in bone marrow cells. a The mean methylation values for both
global CpGs, and DMR-contained CpGs, in annotated regions of the genome are shown. Hypothesis testing was performed using two-way repeated-
measures ANOVA with Tukey’s multiple comparison test within each genomic region. b The density plot of methylation values from whole-genome
bisulfite sequencing (WGBS) for differentially methylated regions (DMRs) defined by comparing Dnmt3a+/+ and germline Dnmt3aR878H/+ for each whole
bone marrow sample from Dnmt3a+/+ (red, n= 10), Dnmt3aR878H/+ (blue, n= 6), Dnmt3a+/- (black, n= 4) and Dnmt3a-/- mice (green, n= 4). c The
mean size (bp) for all DMRs identified in Dnmt3aR878H/+ (n= 2,172), Dnmt3a+/- (n= 8), and Dnmt3a-/- (n= 20,161) bone marrow cells when
independently compared to Dnmt3a+/+ controls (P-values by one-way ANOVA with Tukey’s multiple comparisons test shown). d The heatmap showing
mean methylation values for the 2172 DMRs defined in Panel b for each individual Dnmt3a+/+ and Dnmt3aR878H/+ sample. Values for the same DMRs
were plotted passively for Dnmt3a+/- and Dnmt3a-/- samples. e The heatmap showing mean CpG methylation values for the 20,161 DMRs defined by
comparing the Dnmt3a+/+ and Dnmt3a-/-samples. Values for the same DMRs were plotted passively for Dnmt3aR878H/+ and Dnmt3a+/-. f Examples of
Dnmt3a-dependent hypomethylated regions in the Hoxb cluster (left) and the Rasip1 gene (right). The locations of DMRs in each gene are indicated in
boxes. DMR differentially methylated region, bp base pairs, TSS transcriptional start site.
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Fig. 6 Germline Dnmt3aR878H/+ mice have differentially expressed genes in hematopoietic cells. a tSNE projections of scRNA-seq data from whole bone
marrow samples from Dnmt3a+/+ (left, n= 2) and Dnmt3aR878H/+ (right, n= 2) mice at 1 month and 9 months of age, showing known populations defined
by graph-based clustering and defined by ToppGene. b Population fractions associated with scRNA-seq data shown in Panel a by genotype and age. c and
d Examples of differentially expressed genes identified in both humans and mice, and in more than one graph-based cluster, and associated with a
differentially methylated region; tSNE projection, read counts per cell in all cells, and percentage of myeloid cells expressing Hoxb4 (panel c) and T-cells
expressing Rasip1 (Panel d) are shown (Data are presented as mean values+ /- SEM. P-values by two-tailed t test or Fisher’s exact test for ratios are
indicated, n= 2 biologically independent samples per genotype). PMN polymorphonuclear leukocyte, GMP granulocyte-monocyte precursor.
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that these DMRs were significantly affected by either covariate.
Further, a post hoc sensitivity analysis of defined DMRs using
linear regression to test for the age and sex as covariates revealed
that genotype remained the most important predictor of methy-
lation phenotype. The frequency of DMRs in annotated genomic
locations was similar in both species, for example, DMRs were
found in 7.52% of the gene bodies of R882 mutant human blood
cells, vs. 6.24% of gene bodies in mice with the R878H mutation
(Supplementary Fig. 1). Although direct human to mouse synteny
mapping outside of gene bodies is informatically challenging, we
have found that many of the DMRs within specific genes are
similar between humans and mice. For illustrative purposes, we
have highlighted similarly located DMRs in the HOXB gene
cluster and the RASIP1 gene in both species. Although we do not
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suggest that dysregulation of these specific genes is directly rele-
vant for the DOS phenotype, it is interesting to note that HOXB
cluster genes have been found to be downregulated in children
with autism spectrum disorders40, and that the RASIP1 locus has
been found to be hypomethylated in the blood of children with the
Floating Harbor Syndrome41, which is caused by pathogenic
variants in SRCAP, and associated with facial dysmorphology and
learning disabilities (MIM #136140). The similarity between
phenotypes, DMRs, and DEGs between species suggests that this
mouse model will be useful for the study of the epigenetic phe-
notypes in various organs, and how they may relate to the com-
plex phenotypes observed in patients with this disorder.
Is DOS a leukemia susceptibility syndrome? Evidence from this
and other studies suggest that it is2,4,6,13. Because many of the
recently identified DOS patients are quite young, the lifetime risk of
developing a hematologic malignancy is not yet clear. The incidence
of childhood ALL is 35 per million, and childhood AML, 7 per
million;42 although somatic DNMT3A mutations are common in
adult AML, they are extremely rare in children with AML43. The
number of identified DOS patients worldwide is currently ~200 (J.
Kiernan, personal communication). Several of these patients have
developed hematologic malignancies at an early age. In the largest
series of DOS patients reported to date2, one out of 55 had devel-
oped AML at age 12 (DNMT3AY735S). In this series of 11 patients,
one had presented with AML at age 12 (DNMT3AR882C); an
additional DOS patient with a DNMT3AR882C mutation developed
AML at age 154. With the help of the TBRS Community (a group of
concerned TBRS families that facilitates research for this syndrome;
https://tbrsyndrome.org), we have identified several other children
and young adults with DOS and a history of hematologic malig-
nancies (Ferris, Smith, and Ley, manuscript in preparation),
including a 20-year-old with AML (DNMT3AI310F), a 9-year-old
with Pre-B-ALL (DNMT3AR882H), a 7-year-old with a secondary T-
cell leukemia/lymphoma (DNMT3AR882H), a 34-year-old with
Essential Thrombocytosis (DNMT3AR882H), and a 27-year-old with
Hodgkin Lymphoma (DNMT3AY735C). Importantly, cooperating
mutations in genes identified in DOS patients with AML are similar
to those found in adults with DNMT3A mutant AML, including
FLT3-ITD, NPMc, and PTPN11 (UPN 894912)4. Mouse models
have further established the risk of developing hematopoietic
malignancies: Dnmt3a deficiency is associated with the development
of myeloid, erythroid, B-, and T-cell malignances32,44–50 and
Dnmt3a haploinsufficiency in the germline is associated with the
development of myeloid malignancies after a long latent period30. In
this report, Dnmt3aR878H/+ germline mutations are associated with
the development of spontaneous myeloid and B-cell neoplasms.
Natural history studies in humans will be needed to define the
relative risk of leukemia development for different mutation types
(i.e., haploinsufficiency-like vs. R882 mutations), and the nature of
the genetic and epigenetic events that provoke progression.
Regardless, these data suggest that the children with this disorder
will need to be prospectively monitored for the development of
hematopoietic (and perhaps other) malignancies. Indeed, young
DOS patients have been described with a pituitary macroadenoma51,
a medulloblastoma52, and a dermatofibrosarcoma in one patient in
this study (UPN 228211).
DEGs defined in preleukemic blood cells in this study may
provide some clues regarding the altered epigenetic state that
predisposes to transformation. For example, several HOXB cluster
genes are downregulated in cells expressing DNMT3AR882H.
However, in AML cells, the same genes are often persistently
expressed at high levels53, and genes within this cluster are nor-
mally repressed by methylation of the DERARE element between
the Hoxb4 and Hoxb5 genes54. HOXA and B cluster genes can
also be dysregulated in AML by fusions with NUP9855–61, and
dysregulation is seen in association with MLL translocations62
and NPM1 mutations63. These observations underlie the com-
plexity of HOX gene dysregulation patterns in AML and under-
score the large gaps in our knowledge regarding the events
that govern the progression from preleukemia to overt
transformation.
In summary, the data presented in this report suggest that
many DNMT3A mutations associated with DOS decrease the
methyltransferase activity of DNMT3A, causing a focal, canonical
hypomethylation phenotype. This phenotype is more pronounced
with mutations at R882, probably because of the dominant-
negative effects of these mutations. The germline R878H muta-
tion results in a mouse phenotype that recapitulates many fea-
tures of human patients with the same mutation, strongly
suggesting that this mutation is sufficient to cause the syndrome.
The availability of this model will allow for more precise char-
acterization of the epigenetic states that are responsible for the
various features of this syndrome, and should provide a pre-
clinical model for approaches designed to correct it.
Methods
Primary human peripheral blood samples. All primary DNMT3A overgrowth
syndrome samples were from buffy coat preps from the peripheral blood samples
shipped overnight to Washington University School of Medicine, or obtained
locally. Participation in the study was governed by informed consent obtained from
the parents or guardians of the patients, using protocols that were compliant with
specific ethical regulations for human studies, in accordance with the Declaration
of Helsinki. The consent documents and protocol were approved by the Human
Research Protection Office at Washington University School of Medicine (Protocol
#201011766). Patient and/or family consent included the collection and sharing of
anonymized data with the scientific community, including (but not limited to)
genetic information, nonidentifying personal characteristics (including age, sex,
and ethnicity), and other clinical characteristics. Confirmation of germline
DNMT3A mutations was performed in peripheral blood and buccal swab DNA
with whole-exome sequencing. Of note, the fresh sample utilized for scRNA-seq
from UPN 624400 was obtained after the patient had been treated for acne using
isotretinoin for approximately 3 months.
Generation of mouse model and husbandry. All mice were in the C57BL/6 J
background. Mice with the germline, heterozygous Dnmt3aR878H/+ mutation
(mouse homologue of the human DNMT3AR882H) from the endogenous locus
were produced by crossing the conditional model first described by Guryanova
et al.28 with B6.C-Tg(CMV-cre)1Cgn/J mice (The Jackson Laboratory). A construct
containing a tetracycline-inducible, WT human DNMT3A1 cDNA was introduced
into the C57Bl6/J genome, and founders were crossed with R26-M2rtTA mice in
the B6 background as described in Ketkar et al.29. All mouse studies were per-
formed in accordance with institutional and federal guidelines, were compliant
with all ethical considerations for animal studies, and were approved by the Animal
Studies Committee at Washington University (Protocol 20–0053. Mice were
Fig. 7 Germline Dnmt3a R878H/+ mice develop hematopoietic malignancies. a Dnmt3a+/+ (n= 11) and Dnmt3aR878H/+ (n= 11) mice were treated with 3
mg/kg doxorubicin for days 1–3 and 100mg/kg cytarabine for days 1–5 administered by tail vein injection, and total peripheral blood white cell counts were
assessed before and 24 days after chemotherapy. Individual data points are presented and mean values+ /- SEM are shown. P-values were calculated by
two-way ANOVA and Šídák’s multiple comparisons test. b Kaplan–Meier curve of leukemia-free survival over time for Dnmt3a+/+ (n= 65) and
Dnmt3aR878H/+ mice (n= 79). c) Characteristics of six spontaneous hematopoietic malignancies arising in Dnmt3aR878H/+ mice. dMay–Grünwald Giemsa
stained cytospins of spleen or bone marrow samples from spontaneous malignancies arising in Dnmt3aR878H/+ mice, as summarized in c. WBC (K/uL)
white blood cells (x1000/mL), pre pre-chemotherapy, Post postchemotherapy, y years, Hb (g/dL) hemoglobin (grams/decilitre), PLT (K/uL) platelets
(x1000/mL), MDS myelodysplastic syndrome, AML acute myeloid leukemia, CMML chronic myelomonocytic leukemia.
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housed at 20 degrees Celsius, 65% humidity and dark/light cycle from 5am–7pm.
Peripheral blood was obtained from the retroorbital space with EDTA capillary
tubes (Fisher Scientific) after adequate anesthesia with isoflurane. Femur, tibia, and
pelvis-derived bone marrow cells were collected from mice in PBS supplemented
with 2% FBS (Atlanta Biologicals) and 0.5 mM EDTA pH 8.0. Cell pellets were
treated with Ammonium Chloride/KCl (ACK) red cell lysis buffer and resuspended
in the RPMI/FBS mixture as a working solution. Female mice were utilized for
high-fat diet feeding for weight tracking due to the propensity for male C57Bl/6
mice to gain weight38.
Flow cytometry mouse. The peripheral blood and bone marrow from mouse
femurs and tibias were utilized for flow cytometry applications. Once isolated, cells
were treated with ACK red cell lysis buffer. Cells were stained with combinations of
the following antibodies against cell-surface markers to identify indicated cell types
(all antibodies are from Becton Dickinson unless indicated): CD11b (MI/70,
0.125 μL), Gr-1 (TB6-8C5; Biolegend, 0.5 μL), Ter-119 (Ter119, 0.25 μL), CD71
(C2, 0.5 μL), B220 (RA3-6B2, 1 μL), CD19 (6D5, Biolegend, 0.25 μL), CD3e (145-
2C11, 1 μL), NK1.1 (PK136, 0.5 μL) Sca-1 (D7; Biolegend, 0.0625 μL), c-KIT (2B8,
1 μL), CD34 (RAM34, 2 μL), FLT3 (A2F10; Biolegend, 0.5 μL), CD150 (TC15-
12F12.2; Biolegend, 0.5 μL), CD48 (HM48-1; Biolegend, 0.0625 μL), Ly5.1 (A20,
0.8 μL), Ly5.2 (104, 1 μL). The following phenotypes were used to define stem and
progenitor populations: lineage negative (Lin): CD11b, Gr1, Ter119, CD71, B220,
CD3e, NK1.1; LSK: Lin neg, Sca-1, c-KIT; GMP: Lin neg, Sca-1, c-KIT, CD34,
FLT3; CMP: Lin neg, Sca-1, c-KIT, CD34, FLT3 neg; MEP: Lin neg, Sca-1, c-KIT,
CD34 neg, FLT3 neg; SLAM: Lin neg, Sca-1, c-KIT, CD150, CD48 neg. Human.
Peripheral blood from unaffected controls and DOS patients were utilized for flow
cytometry applications. Antibodies against well-characterized cell-surface receptors
were used to identify indicated cell types (all antibodies are from Becton Dickinson
unless indicated; clone indicated in parentheses): CD45 (HI30, 2 uL), CD3
(UCHT1, 1 uL), CD11b (MI/70, 0.125 μL), CD16 (3G8; BioLegend, 0.5 μL), CD19
(HIB19, BioLegend, 1 μL), CD14 (M5E2, BioLegend, 1 μL), HLA-DR (G46-6, 1 μL),
CD15 (HI98, 1 μL), CD56 (NCAM16.2, 0.5 μL), CD33 (WM53, 0.1 μL), CD11c (B-
ly6, 0.125 μL), CD66b (G10F5, BioLegend, 0.5 μL), CD123 (32703, R&D systems,
0.25 μL), CD303 (REA693, Miltenyi, 0.5 μL). Acquisition was performed using the
ZE5 flow analyzer (Bio-rad) and data were analyzed using FlowJo (Tree Star) and
Prism 9 (GraphPad). Gating strategies are shown in Supplementary Fig. 9.
Whole-genome bisulfite sequencing. WGBS was performed using the AccelNGS
Methyl-Seq DNA library kit (Swift Biosciences, #30096). The sequence was gen-
erated on Illumina HiSeq or NovaSeq instruments and reads were mapped with
biscuit, as described in https://github.com/genome/analysis-workflows/blob/
v1.5.0_fix_1/definitions/pipelines/bisulfite.cwl. The “metilene” algorithm was used
to analyze the methylation ratios at all CpGs to identify differentially methylated
regions (DMRs). Each DMR was required to span >10 CpGs, have a mean
methylation difference between groups of >0.2, and a false discovery rate (FDR)
<0.05. Adjacent DMRs <50 bp apart were merged, then non-canonical DMRs with
standard deviation within either group of >0.1 were removed24. Gene annotations
(gene bodies, transcription start sites, promoters, and enhancers) are based on
protein-coding genes from Ensembl release 95 and its accompanying
regulatory build.
Total RNA-sequencing, processing, and analysis. Total RNA-sequencing of
DNMT3AR882 and healthy control peripheral blood was performed using the
Illumina TruSeq Stranded Total RNA Library Kit29. Alignments were generated
with HISAT as detailed in https://github.com/genome/analysis-workflows/blob/
v1.5.0_fix_1/definitions/pipelines/rnaseq.cwl. Expression quantification was done
using Partek Flow software (version 9.0.20.1125). Differentially expressed genes
were identified using DESeq2 between DNMT3A+/+ vs DNMT3AR882, requiring a
p-value of ≤ 0.05 and a Log2Ratio of ≥1 or ≤−1.
Single-cell RNA library construction and sequencing. Cells were processed using
the 10x Genomics Chromium Controller and the Chromium Single Cell 5′ Library
& Gel Bead Kit (v2.0) following the standard manufacturer’s protocols (https://
tinyurl.com/y96l7lns). Samples were then sequenced on the Illumina NovaSeq (2 ×
150 paired-end reads), yielding a mean of 486,655,675 reads per sample (Data-
set S8). Transcript alignment and counting were performed using the Cell Ranger
pipeline (10x Genomics, default settings, Version 3.0.1). Using a nearest neighbor
algorithm implemented in R (version 3.5.1), cells were annotated according to the
Haemopedia expression atlas of hematopoietic cell types34 using code available
here: (https://github.com/genome/docker-scrna_lineage_inference). Using Partek
Flow software (version 9.0.20.1125), we removed cells that contained fewer than
250 expressed genes, less than 500 total reads, or more than 10% mitochondrial
transcripts. For each cell, the expression of each gene was normalized to the
sequencing depth of the cell, scaled to a constant depth (10,000), and log-
transformed. Dimensionality reduction and visualization were performed with the
t-SNE algorithm. Differentially expressed genes were determined using the
ANOVA algorithm and defined as having an p-value of ≤0.05 and a Log2Ratio of ≥
1 or ≤−1.
Body composition. The fat mass and lean mass of 10 pairs of live Dnmt3a+/+ vs.
Dnmt3aR878H/+ mice were measured using whole-body quantitative magnetic
resonance with an EchoMRI Body Composition Analyzer as described in Nixon
et al.64. Briefly, animals were placed in a thin-walled plastic cylinder with a solid
cylindrical plastic insert added to limit movement. Animals were then subjected to
a low-intensity electromagnetic field that generates a signal that modifies the spin
patterns of hydrogen atoms within tissues, the relaxation curves of which are
altered depending on the content of fat and lean tissue. Canola oil was used as the
standard for measurements.
CT scans. CT scans of four pairs of Dnmt3a+/+ vs. Dnmt3aR878H/+ mice at
30 weeks of age were taken on a Siemens Inveon MM PET/CT scanner and images
were acquired with the Siemens Inveon Research Workstation. All studies were
conducted in the MIR Preclinical Imaging Facility of the Washington University
School of Medicine.
Craniofacial data collection and analysis. We collected 25 landmarks from the
reconstructions of cranium and mandible of WT and R878H mice using Stratovan
checkpoint (www.stratovan.com). Two data collection trials were collected for each
mouse and the average of those trials was used in the analyses.
These landmarks were used in two separate analyses: generalized Procrustes
analysis (GPA)65,66 and Euclidean Distance Matrix Analysis (EDMA)67,68. The
cranial landmarks were analyzed separately from the mandibular landmarks. GPA
was used to complete principal components analysis (PCA), which determines
whether the two groups are different without allowing us to localize the changes.
With GPA, the landmarks are scaled, rotated, and translated to achieve the best fit.
To statistically test for localized differences between the groups of mice for linear
distances, Euclidean Distance Matrix Analyses was used. EDMA statistically
compares linear distances between pairs of landmarks to determine whether the
mice are different for these distances.
Femoral data collection and analysis. Three-dimensional reconstructions of the
mouse femora were completed using Avizo (https://www.thermofisher.com). Using
the Measure tool in this software, the length of the left femur for each mouse was
collected twice. Femur length was calculated as the distance spanning between the
greater trochanter and lateral condyle. The average of the two trials was used to
compare overall femur lengths between the Dnmt3a+/+ vs. Dnmt3aR878H/+ mice
with a Mann–Whitney U-test.
Behavior measurements. All behavioral analyses were performed in collaboration
with the Intellectual and Developmental Disabilities Research Center at
Washington University School of Medicine in St Louis and were recently described
in full by Christian et al39. Mouse numbers used for each significant finding are
indicated in Fig legends. One-hour locomotor activity was evaluated by compu-
terized photobeam instrumentation in transparent polystyrene enclosures (47.6
cm × 25.4 cm × 20.6 cm)69. Activity variables such as ambulation’s and vertical
rearing’s were measured in addition to time spent in a 33 cm × 11 cm central
zone69. Sensorimotor battery assayed walking initiation, balance (ledge and plat-
form tests), volitional movement (pole and inclined screen test), and strength
(inverted screen) were previously described69,70. For the walking initiation test,
mice were placed on the surface in the center of a 21 cm × 21 cm square marked
with tape and the time for the mouse to leave the square was recorded. During the
balance tests, the time the mouse remained on an elevated plexiglass ledge (0.75 cm
wide) or small circular wooden platform (3.0 cm in diameter) was recorded. For the
inclined screen tests, a mouse was placed (oriented head-down) in the middle of an
elevated mesh grid measuring 16 squares per 10 cm angled at 60° or 90°. The time
for the mouse to turn 180° and climb to the top was recorded. For the inverted
screen test, a mouse was placed on a similar screen and when it appeared to have a
secure grasp of the screen, it was inverted 180° and the latency to fall was recorded.
All tests had a duration of 60 s, except for the pole test which was 120 s. Two
separate trials were done on subsequent days, and the average time of both trials
was used for analysis. Morris water maze. Cued trials (visible platform, variable
location) and place trials (submerged, hidden platform, consistent location) were
conducted in which escape path latency, length, and swimming speeds were
recorded. Animal tracking was done using a computerized system (ANY-maze,
Stoelting). During cued trials, animals underwent 4 trials per day over 2 con-
secutive days with the platform being moved to a different location for each trial,
and few distal spatial cues. Each trial lasted no longer than 60 s, with a 30-minute
interval between each trial. Performance was analyzed across four blocks of trials
(two trials/block). After a three-day rest period, animals were tested on Place trials,
in which mice were required to learn the single location of a submerged platform
with several salient distal spatial cues. Place trials occurred over 5 consecutive days
of training, with two blocks of two consecutive trials (60 s trial maximum, 30 s
interatrial-interval after the mouse has reached the platform), and with each block
separated by 2 h. Mice were released into different quadrants over different trials.
Place trials were averaged over each of the five consecutive days (four trials/block).
One hour after the final block, a Probe trial (60 s trial maximum) in which the
platform is removed, and the mouse is released from the quadrant opposite where
the platform had been located. The time spent in pool quadrants and the number
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of crossings over the exact platform location were recorded. Elevated plus maze.
Anxiety-like behaviors were examined using the elevated plus maze71. The appa-
ratus contains a central platform (5.5 cm × 5.5 cm) with two opposing open arms
and two opposing closed arms (each 36 cm × 6.1 cm × 15 cm) constructed of black
Plexiglas. Mouse position is measured using beam-breaks from pairs of photocells
configured in a 16 × 16 matrix, and outputs are recorded using an interface
assembly (Kinder Scientific) and analyzed using software (MotoMonitor, Kinder
Scientific) to determine time spent, distance traveled, and entries made into open
arms, closed arms, and the center area. Test sessions were conducted in a dimly lit
room with each session lasting 5 min, and each mouse tested over three consecutive
days. Conditioned Fear72,73. Mice were habituated to an acrylic chamber (26 cm ×
18 cm x 18 cm) containing a metal grid floor and an odorant, all light with LED
light which remained on for the duration of the trial. Day 1 testing lasted 5 min in
which an 80-dB tone sounded for 20 s at trial timepoints 100, 160, and 220 s. A 1.0
mA shock (unconditioned stimulus) occurred within the last 2 s of the tone
(conditioned stimulus). Baseline freezing behavior during the first 2 min and the
freezing behavior during the last 3 min was quantified using image analysis
(Actimetrics, Evanston, Illinois). On Day 2, testing lasted for 8 min in which the
light was illuminated but no tones or shocks were presented. On day 3, testing
lasted for 10 min in which the mouse was placed in an opaque chamber with a
different odorant than the original test chamber. The 80-dB tone began at 120 s and
lasted for the remainder of the trial, and freezing behavior to the conditioned
auditory stimulus was quantified for the remaining 8 min. Continuous and Accel-
erating Rotarod. Motor coordination and balance was assessed using the rotarod
test (Rotamex-5, Columbus Instruments, Columbus, OH) using three conditions: a
stationary rod (60 s maximum), a rotating rod at constant 5 rpm (60 s maximum),
and a rod with accelerating rotational speed (5–20 rpm, 180 s maximum)70. This
protocol is designed to minimize learning and instead measure motor coordina-
tion, so testing sessions were separated by 4 days to allow for extinction. Testing
included one trial on a stationary rod and two trials on both the constant-speed
rotarod and accelerating rotarod. Marble Burying. Marble burying is a natural
murine behavior and has been used to indicate repetitive digging behavior as well
as anxiety-related behaviors. The protocol was adapted from72,74. Marble burying
assays occurred when the mice were 8 weeks of age. Mice were placed in a
transparent enclosure (28.5 cm × 17.5 cm × 12 cm) with clean aspen bedding and
20 dark blue marbles evenly spaced in a 4 × 5 grid on top of the bedding. Animals
were allowed to explore freely for 30 min, and the number of buried marbles were
counted every 5 min by two independent observers. Marbles were considered
buried if they were at least two-thirds covered by bedding. Between animals,
enclosure, and marbles were cleaned thoroughly.
Plasma glucose, lipid, and leptin measurements. Mice were fasted for 6 h
before isolation of plasma. Glucose was measured utilizing Autokit c, glucose
diagnostic reagent (439–90901) from Wako Chemicals USA Inc., according to
manufacturer’s instructions. Total Cholesterol was measured utilizing Infinity
Total Cholesterol kit (NC9343696) from Fisher Scientific. Free fatty acids were
measured utilizing reagents (999–34691, 995–34791, 991–34891, 993–35191,
276–76491) from Wako chemicals USA Inc. Leptin was measured using Mouse/
Rat Leptin Quantikine ELISA kit (MOB00B) from R&D systems according to
manufacturer’s protocol.
In vivo chemotherapy treatments. Before treatment, mice were retro-orbitally
bled and a complete blood count (CBC) was performed. Mice were treated with 3
mg/kg doxorubicin for days 1–3 administered through tail vein injection and 100
mg/kg cytarabine for days 1–5 administered through tail vein injection. Mice were
retro-orbitally bled to obtain post-treatment CBCs 24 days after the last dose was
administered.
Quantification and statistical analysis. Statistical analysis was performed using
either the software indicated above or in R (4.0.2). Hypothesis testing in R was
performed using chi-square tests for categorical variables, t tests for continuous
variables, Wilcoxon signed-rank tests for comparing means of gene-expression
quartiles, or Fisher’s exact test for differences between proportional data (i.e.,
lineage fractions). All reported significance metrics are corrected for multiple
testing by Benjamini–Holm (FDR), Bonferroni or Yates methods (p-values), unless
otherwise noted.
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Sequencing data for all mouse datasets were deposited to the NCBI, [https://www.ncbi.
nlm.nih.gov/bioproject/PRJNA722276], and are available without restrictions.
Sequencing data for all human datasets were deposited to dbGaP study # phs000159. The
human datasets are available only via this controlled access database because patient
identity can be ascertained from SNPs in whole-genome bisulfite and exome sequencing
data; the IRB that approved this study required this caveat. Applications for access can be
submitted via the dbGaP page. Source data are provided with this paper.
Code availability
All pipeline code used for genomic data processing is available at [https://github.com/
genome/analysis-workflows] (commit id: 174f3b2). Alignment and variant calling from
genomic DNA are under pipelines/somatic_exome.cwl, alignment and expression
quantification is under pipelines/rnaseq.cwl, and bisulfite alignment and methylation
inference is under pipelines/bisulfite.cwl.
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